In this DataPulse video brief, Dr. Muthiah Vaduganathan reviews findings from the SPIRIT-HF trial evaluating spironolactone in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF). He examines trial outcomes related to heart failure hospitalization and cardiovascular death, as well as observed safety findings such as hyperkalemia, renal events, hypotension, and hospitalization rates. Learn about the clinical implications of these findings for the use of steroidal mineralocorticoid receptor antagonists (MRAs) in heart failure management, with particular attention to cardiorenal risk and monitoring burden. The brief also explores emerging interest in nonsteroidal MRAs, including finerenone, and reviews how differences in mechanism, safety profile, and clinical outcomes may inform therapy selection in cardiovascular-kidney-metabolic disease management.
SPIRIT-HF: Does Spironolactone Improve Outcomes in HFpEF and HFmrEF?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Bayer.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medcon. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Overview
In this DataPulse video brief, Dr. Muthiah Vaduganathan reviews findings from the SPIRIT-HF trial evaluating spironolactone in patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF). He examines trial outcomes related to heart failure hospitalization and cardiovascular death, as well as observed safety findings such as hyperkalemia, renal events, hypotension, and hospitalization rates. Learn about the clinical implications of these findings for the use of steroidal mineralocorticoid receptor antagonists (MRAs) in heart failure management, with particular attention to cardiorenal risk and monitoring burden. The brief also explores emerging interest in nonsteroidal MRAs, including finerenone, and reviews how differences in mechanism, safety profile, and clinical outcomes may inform therapy selection in cardiovascular-kidney-metabolic disease management.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Bayer.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medcon. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Title
Program Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?